Hepion director buys stock and 500K warrants

Hepion Pharmaceuticals, Inc. director Gary S. Stetz II reported net purchases on August 3, 2026.

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. director Gary S. Stetz II reported net purchases on August 3, 2026. He acquired 500,000 shares of Common Stock at a price of $0.05 per share, bringing his direct Common Stock holdings to 500,000 shares. He also acquired warrants for 500,000 shares of Common Stock with an exercise price of $0.06 and an expiration date of August 3, 2031, resulting in 500,000 warrants held directly. The Rule 10b5-1 checkbox was not marked, indicating these purchases were not reported as made under a trading plan.

Insider Trade Summary

Net Buyer: 1,000,000 shares

Net Buy 2 txns

Insider Stetz Gary S. II

Role Director

Bought 1,000,000 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Warrants	500,000	$0.00	$0.00
Purchase	Common Stock	500,000	$0.05	$25K

Holdings After Transaction: Warrants — 500,000 contracts (Direct); Common Stock — 500,000 shares (Direct)

Key Figures

Common Stock purchased: 500,000 shares Purchase price per Common share: $0.05 per share Warrants acquired: 500,000 warrants +4 more

7 metrics

Common Stock purchased 500,000 shares Shares of Common Stock purchased on August 3, 2026

Purchase price per Common share $0.05 per share Price paid for Common Stock on August 3, 2026

Warrants acquired 500,000 warrants Warrants to acquire Common Stock, acquired August 3, 2026

Warrant exercise price $0.06 per share Exercise price for warrants exercisable into Common Stock

Warrant expiration August 3, 2031 Expiration date of warrants acquired on August 3, 2026

Common shares held after 500,000 shares Total Common Stock directly held following the transaction

Warrants held after 500,000 warrants Total warrants directly held following the transaction

Key Terms

Warrants, exercise price, expiration date, Rule 10b5-1

4 terms

Warrants financial

"The warrants give the right to purchase 500,000 shares of Common Stock"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

exercise price financial

"warrants for 500,000 shares of Common Stock with an exercise price of $0.06"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"an exercise price of $0.06 and an expiration date of August 3, 2031"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Rule 10b5-1 regulatory

"The Rule 10b5-1 checkbox was not marked, indicating no trading plan"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Hepion Pharmaceuticals (HEPA) director Gary S. Stetz II buy on August 3, 2026?

Gary S. Stetz II purchased 500,000 shares of Common Stock of Hepion Pharmaceuticals at $0.05 per share and acquired warrants for 500,000 shares of Common Stock exercisable at $0.06 per share.

What are the key terms of the warrants acquired by the HEPA director?

The warrants give the right to purchase 500,000 shares of Hepion Pharmaceuticals Common Stock at an exercise price of $0.06 per share, with an expiration date of August 3, 2031, and are held directly by the reporting person.

How many Hepion Pharmaceuticals (HEPA) Common shares does the director hold after these transactions?

After the reported transaction, Gary S. Stetz II holds 500,000 shares of Common Stock directly. He also holds 500,000 warrants for additional Common Stock, separate from his current share ownership position.

Were the HEPA insider’s August 3, 2026 transactions under a Rule 10b5-1 plan?

No. The Form 4’s Rule 10b5-1 checkbox was not checked, indicating the reported purchases of Common Stock and warrants were not reported as executed pursuant to a Rule 10b5-1 trading plan.

What is the total number of HEPA securities the director bought in this Form 4 filing?

In total, the director acquired 1,000,000 HEPA-related securities: 500,000 shares of Common Stock at $0.05 per share and 500,000 warrants exercisable into Common Stock at an exercise price of $0.06 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2026 - 09:43 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stetz Gary S. II

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		P		500,000	A	$0.05	500,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	$0.06	08/03/2026		P		500,000		08/03/2026	08/03/2031	Common Stock	500,000	$0	500,000	D

Explanation of Responses:

	/s/ Gary Stetz, II	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)